Imbria Pharmaceuticals Receives FDA Orphan Drug Designation for Ninerafaxstat for Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

▤ Summary

Imbria Pharmaceuticals announced that the FDA granted Orphan Drug Designation to ninerafaxstat for symptomatic non-obstructive hypertrophic cardiomyopathy. The drug is still in Phase 2b testing in the FORTITUDE-HCM trial, and the company expects topline data in the first half of 2027. The designation may provide development incentives, tax credits, user fee waivers, and potential market exclusivity if the therapy is approved. The update highlights Imbria’s focus on cardiac energy metabolism and its broader development program for rare cardiovascular disease.

▦ Linked Companies